高级检索

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

单剂次HPV疫苗保护作用及接种策略的机遇和挑战

张梦 吴丹 梁晓峰

张梦, 吴丹, 梁晓峰. 单剂次HPV疫苗保护作用及接种策略的机遇和挑战[J]. 中国公共卫生. doi: 10.11847/zgggws1139851
引用本文: 张梦, 吴丹, 梁晓峰. 单剂次HPV疫苗保护作用及接种策略的机遇和挑战[J]. 中国公共卫生. doi: 10.11847/zgggws1139851
ZHANG Meng, WU Dan, LIANG Xiao-feng. Protection efficiency and vaccination strategy of single-dose HPV vaccine: opportunity and challenges[J]. Chinese Journal of Public Health. doi: 10.11847/zgggws1139851
Citation: ZHANG Meng, WU Dan, LIANG Xiao-feng. Protection efficiency and vaccination strategy of single-dose HPV vaccine: opportunity and challenges[J]. Chinese Journal of Public Health. doi: 10.11847/zgggws1139851

单剂次HPV疫苗保护作用及接种策略的机遇和挑战

doi: 10.11847/zgggws1139851
基金项目: 中国疾病预防控制中心公共卫生应急反应机制的运行(131031001000200001)
详细信息
    作者简介:

    张梦(1997 – ),女,陕西咸阳人,硕士在读,研究方向:流行病与卫生统计学

    通讯作者:

    梁晓峰,E-mail:liangxf@jnu.edu.cn

  • 中图分类号: R 186

Protection efficiency and vaccination strategy of single-dose HPV vaccine: opportunity and challenges

  • 摘要: 接种人类乳头瘤病毒(human papilloma virus, HPV)疫苗可预防HPV感染和HPV相关癌症。目前大多数国家采用2剂次HPV疫苗接种方案,但越来越多的研究发现接种单剂次HPV疫苗具有潜在的保护效果。鉴于宫颈癌的巨大全球疾病负担及因HPV疫苗供应紧张而造成国家或地区间的供应日益严重不平等现象,世界卫生组织免疫策略咨询专家组(Strategic Advisory Group of Experts on Immunization, SAGE)在2022年4月相关会议上表明,单剂次HPV疫苗与2剂次或3剂次疫苗接种方案的保护作用相当。本文就HPV疫苗接种现状和单剂次HPV疫苗保护作用的相关研究进行综述,并分析未来实施单剂HPV疫苗接种策略的机遇和挑战。
  • 表  1  单剂次HPV疫苗的保护效力

    研究地点 研究对象 HPV疫苗随访时间(月) 相关指标保护效力
    VE(%)95 % CI
    肯尼亚[23] 15~20岁女性 单剂次九价Gardasil®9 18 HPV16/18持续性感染率 97.5 81.7 ~ 99.7
    单剂次二价Cervarix® 97.5 81.6 ~ 99.7
    坦桑尼亚[24] 9~14岁女性 Cervarix®、Gardasil®9 24 HPV16/18 IgG抗体阳性率 a
    印度[25] 10~18岁女性 单剂次四价Gardasil® 120 HPV16/18持续性感染率 95.4 85.0 ~ 99.9
    2剂次四价Gardasil® 93.1 77.3 ~ 99.8
    3剂次四价Gardasil® 93.3 77.5 ~ 99.7
    哥斯达黎加[26] 18~25岁女性 单剂次二价Cervarix® 135.6 HPV16/18持续性感染率 82.1 40.2 ~ 97.0
    2剂次二价Cervarix® 83.8 19.5 ~ 99.2
    3剂次二价Cervarix® 80.2 70.7 ~87.0
      注:a 接种单剂次Cervarix®、Gardasil®9后,HPV16 IgG抗体阳性率不劣于2剂次和3剂次同种HPV疫苗。
    下载: 导出CSV
  • [1] International Agency for Research on Cancer. GLOBOCAN 2020[EB/OL]. (2022 – 04 – 18)[2022 – 04 – 18]. https://gco.iarc.fr/.
    [2] Toh ZQ, Russell FM, Garland SM, et al. Human papillomavirus vaccination after COVID - 19[J]. JNCI Cancer Spectrum, 2021, 5(2): pkab011. doi: 10.1093/jncics/pkab011
    [3] Shadab R, Lavery JV, McFadden SAM, et al. Key ethical considerations to guide the adjudication of a single - dose HPV vaccine schedule[J]. Human Vaccines and Immunotherapeutics, 2022, 18(1): 1917231. doi: 10.1080/21645515.2021.1917231
    [4] World Health Organization. Vaccination schedule for human papilloma virus[EB/OL]. (2022 – 04 – 01)[2022 – 05 – 06]. https://immunizationdata.who.int/pages/schedule-by-disease/hpv.html?TARGETPOP_GENERAL=ADULTS + GENERAL + FEMALE.
    [5] Sankaranarayanan R, Prabhu PR, Pawlita M, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study[J]. The Lancet Oncology, 2016, 17(1): 67 – 77. doi: 10.1016/S1470-2045(15)00414-3
    [6] Toh ZQ, Russell FM, Reyburn R, et al. Sustained antibody responses 6 years following 1, 2, or 3 doses of quadrivalent human papillomavirus (HPV) vaccine in adolescent Fijian girls, and subsequent responses to a single dose of bivalent HPV vaccine: a prospective cohort study[J]. Clinical Infectious Diseases, 2017, 64(7): 852 – 859.
    [7] Bandyopadhyay S, Pal M. Single dose nonavalent HPV vaccine – need of the hour[J]. Nepal Journal of Epidemiology, 2020, 10(2): 871 – 873. doi: 10.3126/nje.v10i2.28962
    [8] Batmunkh T, Dalmau MT, Munkhsaikhan ME, et al. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immuno-genic and reduces HPV detection rates in young women in Mongolia, six years after vaccination[J]. Vaccine, 2020, 38(27): 4316 – 4324. doi: 10.1016/j.vaccine.2020.04.041
    [9] World Health Organization. SAGE April 2022 meeting highlights[EB/OL]. (2022 – 04 – 11)[2022 – 04 – 18]. https://www.who.int/news/item/11-04-2022-sage-april-2022-meeting-highlights.
    [10] World Health Organization. One-dose human papillomavirus (HPV) vaccine offers solid protection against cervical cancer[EB/OL]. (2022 – 04 – 11)[2022 – 04 – 18]. https://www.who.int/news/item/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer.
    [11] World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2022: conclusions and recommendations[EB/OL]. (2022 – 06 – 17)[2022 – 07 – 23]. https://www.who.int/publications/i/item/who-wer9724-261-276.
    [12] World Health Organization. Human papillomavirus vaccines. WHO position paper[J]. Weekly Epidemiological Record, 2009, 84(15): 118 – 131.
    [13] World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014 – Recommendations[J]. Vaccine, 2015, 33(36): 4383 – 4384. doi: 10.1016/j.vaccine.2014.12.002
    [14] World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017- recommendations[J]. Vaccine, 2017, 35(43): 5753 – 5755. doi: 10.1016/j.vaccine.2017.05.069
    [15] World Health Organization. Meeting of the strategic advisory group of experts on immunization, October 2019: conclusions and recommendations[J]. Weekly Epidemiological Record, 2019, 94(47): 541 – 559.
    [16] Mphuru A, Li AJ, Kyesi F, et al. National introduction of human papillomavirus (HPV) vaccine in Tanzania: programmatic decision - making and implementation[J]. Vaccine, 2022, 40(S1): A2 – A9.
    [17] Stanley M, Dull P. HPV single - dose vaccination: impact potential, evidence base and further evaluation[J]. Vaccine, 2018, 36(32): 4759 – 4760. doi: 10.1016/j.vaccine.2018.02.076
    [18] Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices[J]. Morbidity and Mortality Weekly Report, 2019, 68(32): 698 – 702. doi: 10.15585/mmwr.mm6832a3
    [19] World Health Organization. Progress and challenges with achiev-ing universal immunization coverage[EB/OL]. (2020 – 07 – 14)[2022 – 05 – 04]. https://www.who.int/publications/m/item/progress-and-challenges-with-achievinguniversal-immunization-coverage.
    [20] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209 – 249. doi: 10.3322/caac.21660
    [21] World Health Organization. Global strategy to accelerate the elimina-tion of cervical cancer as a public health problem[EB/OL]. (2020 – 11 – 17)[2022 – 04 – 27]. https://www.who.int/publications/i/item/9789240014107.
    [22] Bruni L, Saura-Lázaro A, Montoliu A, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010 – 2019[J]. Preventive Medicine, 2021, 144: 106399. doi: 10.1016/j.ypmed.2020.106399
    [23] Barnabas RV, Brown ER, Onono MA, et al. Efficacy of single - dose human papillomavirus vaccination among young African Women[J]. NEJM Evidence, 2022, 1(5): EVIDoa2100056.
    [24] Watson-Jones D, Changalucha J, Whitworth H, et al. Immuno-genicity and safety results comparing single dose human papillo-mavirus vaccine with two or three doses in Tanzanian girls – the DoRIS Randomised Trial[EB/OL]. (2022 – 03 – 11)[2022 – 05 – 10]. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4055429#.
    [25] Basu P, Malvi SG, Joshi S, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study[J]. The Lancet Oncology, 2021, 22(11): 1518 – 1529. doi: 10.1016/S1470-2045(21)00453-8
    [26] Kreimer AR, Sampson JN, Porras C, et al. Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial[J]. Journal of the National Cancer Institute, 2020, 112(10): 1038 – 1046. doi: 10.1093/jnci/djaa011
    [27] Oliver SE, Unger ER, Lewis R, et al. Prevalence of human papillomavirus among females after vaccine introduction-national health and nutrition examination survey, United States, 2003 – 2014[J]. The Journal of Infectious Diseases, 2017, 216(5): 594 – 603. doi: 10.1093/infdis/jix244
    [28] Spinner C, Ding LL, Bernstein DI, et al. Human papillomavirus vaccine effectiveness and herd protection in Young Women[J]. Pediatrics, 2019, 143(2): e20181902. doi: 10.1542/peds.2018-1902
    [29] Kim JJ. Could 1 dose be less efficacious than 2 doses but still be a great public health intervention?[EB/OL]. (2019 – 09 – 06)[2022 – 05 – 09]. https://www.hpvworld.com/media/29/media_section/0/5/1605/kim.pdf.
    [30] Canfell K, Kim JJ, Brisson M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low - income and lower - middle - income countries[J]. The Lancet, 2020, 395(10224): 591 – 603. doi: 10.1016/S0140-6736(20)30157-4
    [31] Our World in Data. Share of adolescent girls vaccinated against the human papillomavirus, 2020[EB/OL]. (2022 – 05 – 10)[2022 – 05 – 10]. https://ourworldindata.org/grapher/coverage-of-the-human-papillomavirus-vaccine?country=Africa ~ Asia ~ Europe + and + North + America ~ Latin + America + and + the + Caribbean ~ Oceania ~ OWID_WRL.
    [32] Prem K, Choi YH, Bénard É, et al. Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis[EB/OL]. (2021 – 02 – 08)[2022 – 05 – 10]. https://www.medrxiv.org/content/10.1101/2021.02.08.21251186v1.
    [33] Burger EA, Campos NG, Sy S, et al. Health and economic benefits of single - dose HPV vaccination in a Gavi-eligible country[J]. Vaccine, 2018, 36(32): 4823 – 4829. doi: 10.1016/j.vaccine.2018.04.061
    [34] World Health Organization. Report of the meeting on HPV vaccine coverage and impact monitoring[EB/OL]. (2019 – 11 – 20)[2022 – 05 – 18]. https://www.who.int/publications/i/item/WHO_IVB_10.05.
  • 加载中
表(1)
计量
  • 文章访问数:  68
  • HTML全文浏览量:  12
  • PDF下载量:  9
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-07-25
  • 网络出版日期:  2023-01-10

目录

    /

    返回文章
    返回